8:30pm est

BTV Showcases Plant-Based Food, Smart Tech and ETF Investments

On national TV Sat. Aug 7 & Sun. Aug 8, 2021 - BTV-Business Television looks at investment opportunities ranging from plant-based foods to data intelligence.

Discover Companies to Invest In - Click company name to watch their TV feature:

Boosh Food Inc. (CSE: VEGI) - Making plant-based ready-to-eat meals that are gluten-free and non-GMO more accessible and delicious.

Danavation TechnologiesCorp. (CSE: DVN) - Revolutionizing the world of automated product and price labelling, BTV highlights this company's Digital Smart Labels™.

Killi Ltd.(TSXV: MYID) (OTCQB: MYIDF) - BTV learns how this technology allows consumers to take control of their online data and be compensated for it.

Fobi AI Inc. (TSXV: FOBI) (OTCQB: FOBIF) - With their innovative AI device to provide real time data connectivity to retailers.

BMO Global Asset Management (TSX: ZESG) (TSX: ESGG) - ESG: environmental, social and governance investing is gaining popularity - BTV discovers why BMO's ETF are at the helm.

Airing on Biz Television Network - Sun Aug 15 @ 8:30am EST:

iMining Technologies Inc. (TSXV: IMIN) - BTV visits this company focused on linking traditional capital markets with blockchain investment opportunities.

On air for more than 20 years, BTV - Business Television, a half-hour investment TV show, features analysts and emerging companies on location. With Hosts, Taylor Thoen and Jessica Katrichak, BTV brings viewers investment opportunities.


BNN Bloomberg - Saturday Aug 7 @ 8:00pm EST, Sunday Aug 8 @ 4:30pm EST
Bell Express Vu - Saturday Aug 7 @ 8:00pm EST, Sunday Aug 8 @ 4:30pm EST

US National TV:
Biz Television Network - Sun Aug 15 @ 8:30am EST

Suggest a Company to Feature!

Contact: (604) 664-7401 x3 info@b-tv.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92253

News Provided by Newsfile via QuoteMedia

The Conversation (0)


Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday Nov. 29, 2023. Peter H. Griffith executive vice president and chief financial officer at Amgen, and Paul Burton senior vice president and chief medical officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less


New Repatha ® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C

Olpasiran Research Provides Further Insights Into Cardiovascular Risks Associated With Elevated Lp(a)

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Hydralyte International (ASX:HPC)

Hydralyte International

Keep reading...Show less
double helix molecule with ETFs stock chart

5 Small Biotech ETFs to Watch (Updated 2023)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of November 6, 2023. All other figures were also current as of that date.

Keep reading...Show less


FOREMOST Study Finds Oral Otezla ® (apremilast) Significantly Improved Disease Control vs. Placebo

Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla ® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years. Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News